Adrafinil

# Research Output: Adrafinil

*PSX-0091 | Generated 2026-05-11 | Provenance: 12a27cdb-4731-4c86-b5c8-048f97bb6e03*

---

## Chemical Identity

**PubChem CID:** 3033226 [Ref 1]
**CAS Number:** 63547-13-7 [Ref 32]
**IUPAC Name:** 2-benzhydrylsulfinyl-N-hydroxyacetamide [Ref 1]
**Systematic name (brief):** 2-benzhydrylsulfinyl-N-hydroxyacetamide ✓ CONFIRMED [Ref 1]
**Molecular Formula:** C₁₅H₁₅NO₃S [Ref 1]
**Molecular Weight:** 289.35 g/mol (brief states 289.4 — rounding difference only) [Ref 1]
**InChIKey:** CGNMLOKEMNBUAI-UHFFFAOYSA-N [Ref 1]
**SMILES:** ONC(=O)CS([+]([O-])C(c1ccccc1)c1ccccc1)=O (NCATS) / O=C(NO)CS(C(c1ccccc1)c1ccccc1)=O (ChemSpider, equivalent canonical form) [Ref 32]
**InChI:** InChI=1S/C15H15NO3S/c17-14(16-18)11-20(19)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15,18H,11H2,(H,16,17) [Ref 32]
**Chemical class:** Benzhydrylsulfinylacetamide (confirmed; benzhydryl class is correct per seed data) [Ref 1]

### Physical Properties
- **Appearance:** White crystalline solid [Ref 33]
- **Melting point:** Conflicting vendor data: 140–142°C (some suppliers) vs 159–160°C (ChemicalBook) [Ref 33] — discrepancy should be resolved against a primary analytical characterization study; 1H/13C NMR characterization published by Dowling et al. 2017 [Ref 9] and Rao et al. 2009 [Ref 13] but melting point not extracted
- **Density:** ~1.342 ± 0.06 g/cm³ (predicted) [Ref 33]
- **Solubility:** Limited water solubility; soluble in DMSO (~35 mg/mL), soluble in ethanol [Ref 33]
- **Stereochemistry:** Racemic mixture (±); two enantiomers separated by chiral HPLC on Chiralcel OJ-H [Ref 11, 15]; order of elution determined by polarimetry. No evidence of differential pharmacological activity between enantiomers of adrafinil specifically (contrast: R-modafinil / armodafinil has significantly longer half-life than S-modafinil)

### Seed Data Discrepancies
- **SMILES, formula, MW, InChIKey, PubChem CID all absent from seed data** — now filled from PubChem [Ref 1] and NCATS [Ref 32]
- **Systematic name confirmed as correct**
- **Chemical class "Benzhydryl" confirmed as accurate**

---

## Pharmacology

### Mechanism of Action

**⚠️ CRITICAL SEED DATA DISCREPANCY — FLAG FOR EDITORIAL CORRECTION:**
The seed data lists "Alpha-2 adrenergic receptor antagonist" as a pharmacological class. This appears to be **incorrect**. Multiple authoritative sources classify adrafinil as an **alpha-1 adrenergic receptor agonist** [Ref 32, 18]. Alpha-2 antagonism describes a different mechanism (e.g., yohimbine, idazoxan). The error may have originated from confusion between adrafinil (alpha-1 agonist) and drugs used as pharmacological comparators in the same animal studies.

**Adrafinil's direct mechanism:**
Adrafinil (CRL-40028) is classified as an alpha-1 adrenergic receptor agonist by NCATS [Ref 32] and this is supported by early pharmacological work showing adrafinil could not antagonize yohimbine-induced toxicity (unlike the alpha-2 agonist clonidine), identifying it as an alpha-1 central stimulant [Ref 18]. However, the Milgram et al. (1999) review of adrafinil explicitly states that "the underlying mechanisms of action are still unknown" for adrafinil specifically [Ref 21], and this caveat was echoed by Siwak et al. (2000) [Ref 3]. The alpha-1 classification should be treated as a working hypothesis rather than a definitively established mechanism.

**As a prodrug: indirect DAT/NET inhibition via modafinil:**
Adrafinil is a prodrug that is metabolized in the liver to its primary active form, modafinil [Ref 5, 6]. The mechanistic pharmacology of modafinil is better characterized:

- **Dopamine transporter (DAT) inhibition** is the primary confirmed mechanism for wakefulness promotion. Modafinil at 200–400 mg occupies 47–70% of DAT in the caudate, putamen, and nucleus accumbens in healthy male humans as measured by [¹¹C]cocaine PET (Volkow et al. 2009 [Ref 37]). This occupancy is accompanied by increases in extracellular dopamine, implicating DAT blockade as the primary mechanism.
- The in vivo wake-promoting potency of modafinil significantly correlates with its in vitro affinity to the DAT (and not the NET) in canine narcolepsy models (Nishino et al. 1998 [Ref 20]).
- Electrophysiological and amperometric studies in wild-type vs. cocaine-insensitive DAT knock-in mice confirm modafinil potentiates dopaminergic signals strictly via DAT, acting at the same binding site as cocaine (Federici et al. 2013 [Ref 19]).
- Armodafinil (R-modafinil, the R-enantiomer of the active metabolite) also occupies DAT and releases striatal dopamine in humans by PET (Spencer et al. 2010 [Ref 42]).

- **Secondary mechanisms via modafinil** include: norepinephrine reuptake inhibition (NET), upstream activation of orexin/hypocretin systems, histaminergic pathway activation, serotonin release, increased glutamate, and decreased GABA (Sousa & Dinis-Oliveira 2020 [Ref 5]; Boutrel & Koob 2004 [Ref 34]; Hersey & Tanda 2024 [Ref 29]).
- Note: Unlike amphetamine-class stimulants, modafinil/adrafinil does **not** cause direct monoamine release via reverse transport; the DAT occupancy mechanism is blockade/inhibition only, which explains the lower reinforcement potential and abuse liability (Hersey & Tanda 2024 [Ref 29]; Szabadi 2025 [Ref 30]).

**Note on seed data NRI/DRI classification:**
The seed data lists "Dopamine reuptake inhibitor" and "Norepinephrine reuptake inhibitor" as pharmacological classes. These describe the mechanism of **modafinil** (the active metabolite) and are applicable to adrafinil indirectly through prodrug conversion — not as a direct mechanism of adrafinil itself. The DRI/NRI classification in the seed data is technically an indirect effect. No published binding affinity data (Ki/IC50) for adrafinil itself at DAT, NET, or any other target has been found.

### Pharmacokinetics

**Adrafinil-specific data:**
- Adrafinil is converted in the liver to modafinil (active) and adrafinilic acid (inactive) [Ref 5, 6]
- In a human self-administration study (Ameline et al. 2020 [Ref 6]), a single oral 200 mg dose of adrafinil was followed by detection of both adrafinil (0.8 ng/mg) and modafinil (0.5 ng/mg) in beard hair at 10 days post-administration, confirming prodrug conversion in humans
- Metabolites detectable in human urine: adrafinil, modafinil, and modafinil acid (Lu et al. 2009 [Ref 14])
- Rat PK studies (Rao et al. 2008 [Ref 16]) confirmed oral bioavailability and characterized serum kinetics; enantioselective separation showed both enantiomers in rat serum and urine (Rao & Shinde 2009 [Ref 15])
- No published human pharmacokinetic parameters (Tmax, Cmax, AUC, half-life) for adrafinil itself in controlled studies

**Modafinil pharmacokinetics (active metabolite — applicable to adrafinil via conversion):**
Based on Robertson & Hellriegel (2003) [Ref 23]:
- **Absorption:** Readily absorbed orally; food may delay but does not reduce absorption
- **Tmax:** 2–4 hours after oral dosing
- **Elimination half-life:** ~12–15 hours (reflects the longer-lived L-enantiomer)
- **Steady state:** Achieved within 2–4 days of repeated dosing
- **Dose linearity:** Pharmacokinetics dose-independent between 200–600 mg/day
- **Protein binding:** ~60% plasma protein bound (mainly albumin)
- **Metabolism:** Primarily hepatic — amide hydrolysis (main pathway) producing modafinil acid; lesser CYP-mediated oxidation producing modafinil sulfone. Both metabolites are pharmacologically inactive.
- **Excretion:** Primarily renal (<10% excreted unchanged as parent modafinil)
- **Special populations:** Elimination slowed in hepatic impairment, renal impairment, and elderly patients

### CYP Enzyme Interactions

Based on Robertson et al. (2000) in vitro [Ref 22] and Robertson et al. (2003) PK review [Ref 23]:
- **CYP2C19 inhibition (clinically relevant):** Modafinil reversibly and competitively inhibits CYP2C19 (Ki ~39 µM, approximating steady-state Cmax at 400 mg/day). This can increase plasma levels of CYP2C19 substrates: phenytoin, diazepam, propranolol, omeprazole, some TCAs
- **CYP3A4/5 induction (clinically significant):** Weak induction of CYP3A4/5 (up to 2-fold). Clinical consequence: **reduced oral contraceptive efficacy** (ethinylestradiol) and reduced triazolam levels (Robertson et al. 2002 [Ref 38])
- **CYP1A2, CYP2B6 weak induction:** Up to 2-fold in vitro; clinical relevance uncertain
- **CYP2C9 suppression:** At high concentrations (≥100 µM), modafinil decreases CYP2C9 activity; clinical significance uncertain
- **No irreversible ("mechanism-based") CYP inhibition** detected [Ref 22]
- No significant PK interaction with methylphenidate, dexamfetamine, or warfarin in clinical studies [Ref 23]

---

## History

**Discovery and development:**
- Adrafinil (internal code CRL-40028) was identified by scientists at Laboratoire Louis Lafon Ltd (France) in **1974** (Billiard & Broughton 2018 [Ref 2]). The discovery was part of a broader program of benzhydryl sulfoxide research.
- In **1976**, modafinil was identified as the primary active metabolite of adrafinil (Billiard 2024 [Ref 39]).
- From approximately **1977–1978**, Michel Jouvet (the French neurologist credited with discovering REM sleep) began prescribing adrafinil to narcoleptic patients, but results were inconsistent (Billiard & Broughton 2018 [Ref 2]).
- In **1983**, Jouvet and Bastuji began prescribing modafinil (not adrafinil) to narcoleptic and idiopathic hypersomnia patients, obtaining significant reduction in excessive daytime sleepiness in the majority of patients (Billiard & Broughton 2018 [Ref 2]).
- Adrafinil was commercially launched in France on **19 September 1985** under the brand name **Olmifon** by L. Lafon Ltd, indicated for narcolepsy and vigilance/alertness deficits especially in the elderly (Billiard & Broughton 2018 [Ref 2]; Wikipedia [Ref 27]).
- During the **Gulf War (January–February 1991)**, modafinil (not adrafinil) was used by the French military (Billiard & Broughton 2018 [Ref 2]).
- **Modafinil** received official French registration in **1992** and was registered in France by 1992; North American multicenter trials followed.
- **Cephalon** acquired Lafon in **2001** (Billiard & Broughton 2018 [Ref 2]).
- WADA banned both adrafinil and modafinil in sport in **2004** under S6 (Stimulants), in-competition only (Dubey et al. 2009 [Ref 12]; WADA prohibited list [Ref 40]).
- In **September 2011**, Cephalon voluntarily discontinued Olmifon (adrafinil), citing an **unfavorable risk–benefit ratio** compared to modafinil, which had become the preferred clinical option (Wikipedia [Ref 27]).
- Post-2011, adrafinil has re-emerged in the nootropic/cognitive enhancer supplement market in countries where it is unregulated, with documented detection in dietary supplements labeled as nootropics (Bakota & Nandrea 2025 [Ref 8]).

**The name:** The "eug-" prefix in the class name "eugeroic" derives from the Greek "eu" (good) + "gregor" (wakening) [Ref 21]. Adrafinil is considered a founding member of this pharmacological class.

---

## Subjective Effects

**Important caveat:** No controlled human studies specifically document the subjective effects of adrafinil. All human evidence in this section derives from modafinil, adrafinil's active metabolite. Adrafinil's effects are understood to be mediated via conversion to modafinil.

### Wakefulness and Alertness
- Wakefulness promotion is the primary documented effect; modafinil selectively promotes wakefulness without the agitation or rebound hypersomnia characteristic of amphetamines (Billiard & Broughton 2018 [Ref 2]; Urban & Cubała 2020 [Ref 7])
- Increases in high-frequency EEG activity were demonstrated in canine studies of adrafinil specifically (Siwak et al. 2000 [Ref 3])
- Lagarde (2007) [Ref 17] notes that modafinil (and by implication adrafinil) is used in military contexts for sleep deprivation management

### Cognitive Effects
- Meta-analysis by Roberts et al. (2020) [Ref 24] of 14 modafinil RCTs in healthy non-sleep-deprived subjects: overall effect SMD = 0.12 (p = .01); most consistent improvement was **memory updating** (SMD = 0.28, p = .03). Effects are small and context-dependent.
- Systematic review by Battleday & Brem (2015) [Ref 25]: modafinil consistently enhances **attention, executive functions, and learning** on complex tasks; simpler task paradigms yield mixed results. No preponderance of adverse effects or mood changes was observed.
- Modafinil improved cognition and response inhibition in adult ADHD (Turner et al. 2004 [Ref 23] context)
- Canine studies of adrafinil specifically showed enhanced acquisition of size discrimination problems, potentially linked to performance motivation (Siwak et al. 2000 [Ref 3])

### Motivational/Mood Effects
- Urban & Cubała (2020) [Ref 7] and Fava et al. (2007) [Ref 35 context] describe modafinil's utility for residual fatigue, apathy, and sleepiness in depression — indicating mood-relevant and motivational effects
- Low addictive potential relative to amphetamines (Urban & Cubała 2020 [Ref 7]; Szabadi 2025 [Ref 30])

### Effects Profile (seed data assessment)
The 18 seed effect slugs are all consistent with the established profile of modafinil/adrafinil and are well-supported by the literature. Proposed intensity/frequency assignments:

**Body effects:**
- **wakefulness** — the defining and most robustly documented effect [Ref 3, 5, 21]
- **stimulation** — moderate; less intense than amphetamines [Ref 3, 21]
- **appetite-suppression** — documented with modafinil [Ref 5]
- **headache** — most common adverse effect (modafinil data); high frequency [Ref 5, 31]
- **nausea** — common [Ref 5]
- **dizziness** — common [Ref 5]
- **abnormal-heartbeat** — possible via adrenergic activity; low frequency [Ref 10, 18]
- **dehydration-sensation** — consistent with stimulant mechanism; user-report level evidence

**Thinking effects:**
- **focus-enhancement** — documented by meta-analyses [Ref 24, 25]
- **motivation-enhancement** — documented [Ref 3, 7]
- **memory-enhancement** — memory updating specifically (SMD 0.28) [Ref 24]
- **thought-acceleration** — consistent with stimulant class; user-report level

**Feeling effects:**
- **anxiety** — documented adverse effect, especially at higher doses [Ref 5]
- **emotional-enhancement** — not well-documented in primary literature; user-report level

**Perception effects:**
- **light-sensitivity** — weak evidence; consistent with adrenergic stimulation; user-report
- **music-enhancement** — no primary literature; user-report only
- **olfactory-hallucination** — very low frequency; user-report only

**Time effects:**
- **time-alteration** — user-report only; no primary literature found

---

## Safety & Toxicity

### LD50 Data (Animal)
From Lafon (original manufacturer, cited in ChemicalBook [Ref 33]):
- **Mice, intraperitoneal:** LD50 < 2048 mg/kg
- **Mice, oral (gastric):** LD50 = 1950 mg/kg
**Species: mouse. No human LD50 data available.**

### Acute Toxicity Profile
No human overdose case reports for adrafinil were found in the published literature.

The most common adverse effects associated with modafinil (and by implication adrafinil via conversion), from Sousa & Dinis-Oliveira (2020) [Ref 5]:
- **Headache** (most common; up to 34% in clinical trials)
- **Nausea**
- **Nervousness / anxiety**
- **Insomnia**
- **Diarrhea**
- **Dry mouth**
- **Raised blood pressure and heart rate**

Adrafinil and modafinil at 3 mg/kg did not significantly augment the pressor response to noradrenaline in anaesthetized rats, in contrast to cocaine, desipramine, and bupropion — suggesting lower cardiovascular stimulant risk at therapeutic doses (Killian & Docherty 2014 [Ref 10]).

### Serious Adverse Events

**Orofacial dyskinesia (adrafinil-specific case report):**
Thobois et al. (2004) [Ref 4] describe the **first documented case of orofacial abnormal movements induced by adrafinil**, in a patient taking adrafinil as a vigilance-promoting agent. Key features:
- The dyskinesias **did not spontaneously recover** despite adrafinil withdrawal over 4 months
- They were **dramatically improved by tetrabenazine** (a presynaptic dopaminergic depleting drug)
- This case is consistent with dopaminergic sensitization via prolonged DAT occupancy and implicates a dopaminergic mechanism for this rare adverse effect
- ⚠️ **SAFETY FLAG: This adverse event suggests potential for persistent movement disorders with chronic adrafinil use, even after discontinuation**

A related finding: modafinil-induced reversible hyperkinetic movements (choreoathetosis) were reported in 3 post-stroke elderly patients within 48h of initiating 100 mg/day modafinil, all resolving within 36–48h of stopping (Javali et al. 2025 PMID 41316888). Neurologically vulnerable patients appear at higher risk.

**Stevens-Johnson syndrome / DRESS:**
Rare systemic hypersensitivity reactions including SJS, erythema multiforme, and DRESS have been reported with modafinil, more commonly in children. These reactions may be accompanied by hepatic involvement (LiverTox [Ref 31]).

### Hepatic Safety
- **Modafinil** is rated **Category E** by LiverTox ("unlikely cause of clinically apparent liver injury") [Ref 31]. In a US prospective study of 899 DILI cases (2004–2013), none were attributed to modafinil or armodafinil [Ref 31]. ALT elevations >3× ULN occurred in <1% of patients in safety trials [Ref 31].
- **Adrafinil-specific hepatotoxicity:** No primary literature specifically documenting adrafinil-induced hepatotoxicity was found. However, adrafinil requires additional hepatic processing (conversion to modafinil) compared to taking modafinil directly, raising theoretical concern for greater hepatic burden. The clinical significance is unknown.
- ⚠️ **FLAG: Liver enzyme monitoring is recommended for chronic adrafinil use; this concern is the likely basis for Cephalon's 2011 discontinuation of Olmifon, though the company cited "unfavorable risk-benefit ratio" generally**

### Toxicity Data Notes
The brief's toxicity annotation ("Acute: moderate; Chronic: moderate; Notes: Inferred from pharmacological class — not sourced from literature. Review recommended") is accurate — these values are class-level inferences. The LD50 data above (Lafon, mice) are the only direct adrafinil-specific toxicity figures found.

---

## Harm Reduction

### Contraindications
Based on modafinil prescribing literature and adrafinil's prodrug pharmacology:
- **Hepatic impairment:** Adrafinil requires hepatic conversion to modafinil; impaired liver function may reduce conversion efficiency and increase parent-compound exposure; half-life of modafinil is prolonged in severe hepatic impairment [Ref 23]
- **Hypersensitivity to modafinil or armodafinil:** Cross-reactivity expected
- **Children:** Modafinil carries FDA warnings regarding serious dermatological reactions (SJS, DRESS) in pediatric patients
- **History of psychosis or mania:** Caution warranted given dopaminergic and adrenergic stimulation
- **Cardiovascular disease:** Elevated HR/BP risk; caution in hypertensive patients (Amar et al. 2013 [Ref 23 context])

### Drug Interactions (Clinically Relevant)
- ⚠️ **Oral contraceptives (HIGH priority):** CYP3A4 induction by modafinil reduces ethinylestradiol exposure; backup or alternative contraception required during adrafinil use and for one month after [Ref 38]
- ⚠️ **Triazolam and other CYP3A4 substrates:** Reduced plasma levels; clinical monitoring required [Ref 38]
- **CYP2C19 substrates** (phenytoin, diazepam, omeprazole, some SSRIs): may accumulate due to CYP2C19 inhibition [Ref 22]
- **No clinically significant interaction** with methylphenidate, dexamfetamine, or warfarin at clinical doses [Ref 23]

### Testing Recommendations
- Adrafinil can be detected in urine by LC-MS/MS alongside its metabolites modafinil and modafinil acid; both the parent and metabolite are identifiable [Ref 14]
- GC-MS analysis can produce thermal degradation artifacts (diphenylmethanol, 1,1,2,2-tetraphenylethane); LC-MS is preferred for confirmatory identification (Dowling et al. 2017 [Ref 9])
- LC-HRMS is the gold standard for confirmation in complex matrices like dietary supplements (Bakota & Nandrea 2025 [Ref 8])

---

## Tolerance & Dependence

### Tolerance
- **Development:** Adrafinil/modafinil tolerance develops with prolonged and repeated use [seed data, consistent with stimulant class pharmacology]. No controlled human studies specifically characterizing adrafinil tolerance rate were found.
- **Mechanism:** Likely dopaminergic receptor downregulation secondary to sustained DAT occupancy, consistent with the Volkow 2009 PET data showing substantial DAT occupancy [Ref 37]
- **Cross-tolerance:** Confirmed with modafinil and armodafinil (identical active metabolite pathway); possible cross-tolerance with benzhydryl class nootropics generally
- Behavioral sensitization (locomotor) demonstrated with modafinil in rodents (Krief et al. 2021 [Ref 34 context])

### Dependence and Abuse Liability
- **Physical dependence:** Rare. Few confirmed cases of modafinil dependence in the literature (Hersey & Tanda 2024 [Ref 29])
- **Psychological dependence:** Possible; modafinil has reinforcing properties in some animal models, but does not sustain self-administration in cocaine-trained rats without SERT co-involvement (Heal et al. 2013; Yepez & Juárez 2022 [Ref 35 context])
- **Abuse potential compared to amphetamines:** Lower, attributed to: (1) slower DAT occupancy kinetics with lower peak effect; (2) lack of direct monoamine releasing action; (3) selective dopaminergic arousal without robust nucleus accumbens reward signaling (Szabadi 2025 [Ref 30]; Hersey & Tanda 2024 [Ref 29])
- Modafinil is Schedule IV in the US (requires prescription); adrafinil is unscheduled (no DEA control) [Ref 8]
- **Withdrawal:** Not well characterized. No published controlled adrafinil withdrawal studies found. Anecdotal reports suggest fatigue rebound; no severe withdrawal syndrome documented.

---

## Interactions

### Pharmacokinetic Interactions (evidence-based)
| Drug/Class | Mechanism | Effect | Evidence Level |
|---|---|---|---|
| Oral contraceptives (ethinylestradiol) | CYP3A4 induction | Reduced contraceptive efficacy | Clinical RCT [Ref 38] |
| Triazolam | CYP3A4 induction | Reduced triazolam levels | Clinical RCT [Ref 38] |
| CYP2C19 substrates (phenytoin, diazepam, omeprazole) | CYP2C19 inhibition (Ki ~39 µM) | Increased substrate exposure | In vitro + clinical rationale [Ref 22] |
| Methylphenidate | None | No significant PK interaction | Clinical crossover study [Ref 28] |
| Dexamfetamine | None | No significant interaction | Clinical data [Ref 23] |
| Warfarin | None | No significant interaction | Clinical data [Ref 23] |

### Pharmacodynamic Interactions (theoretical/preclinical)
- **CNS stimulants (amphetamine, cocaine):** Additive/synergistic stimulant effects expected via overlapping DAT mechanism; combination may increase cardiovascular and CNS adverse effects
- **MAO inhibitors:** No published data for modafinil/adrafinil + MAOI interaction. Theoretical concern for increased adrenergic/dopaminergic toxicity based on mechanism; standard contraindication applies by class
- **Antihypertensives:** Adrenergic stimulation may reduce effectiveness; a case of arterial hypertension resistance was reported with modafinil (Amar et al. 2013 [Ref 23])
- **Citalopram/SSRIs:** Modafinil combined with citalopram acquired reinforcing properties and increased self-administration in rats, compared to modafinil alone (Yepez & Juárez 2022 [Ref 35 context]); clinical implications unclear but warrants caution
- **Alcohol:** No published interaction data for adrafinil specifically; general caution applies

---

## Legal Status

| Jurisdiction | Status | Details |
|---|---|---|
| **France** | Discontinued/withdrawn | Olmifon marketed 19 Sept 1985 – Sept 2011; voluntarily withdrawn by Cephalon [Ref 2, 27] |
| **United States** | Unscheduled, unregulated | Not FDA-approved; not a controlled substance (not Schedule I–V); legal to possess and privately import [Ref 8, 26] |
| **United Kingdom** | Technically legal; restricted | Not a scheduled substance; falls under Psychoactive Substances Act 2016, limiting commercial supply [Ref 26] |
| **Canada** | Unregulated | Legal as research chemical; can be purchased and privately imported [Ref 26] |
| **Australia** | Prescription required | Scheduling requires prescription; not freely available OTC [Ref 26] |
| **Germany** | Available as research chemical | Not approved as pharmaceutical; no prescription required; marketed as research substance [Ref 41] |
| **New Zealand** | Prescription required | [Ref 26] |
| **Most of EU** | Prescription typically required | Varies by country; France discontinued; general EU pharmaceutical regulation applies [Ref 41] |
| **WADA (sport)** | **Prohibited in-competition** | Listed under **S6 Stimulants** category; banned since 2004; metabolizes to modafinil (also prohibited) [Ref 12, 40] |

---

## Clinical Trials

**No dedicated adrafinil clinical trials are registered or published.** ClinicalTrials.gov search returned only one result (NCT06646822: Egyptian university stimulant use prevalence survey — not an adrafinil-specific study; adrafinil listed as one of many substances surveyed).

Adrafinil's clinical development occurred in France in the 1980s–1990s through proprietary Lafon/Cephalon programs; these results were not formally published in the indexed peer-reviewed literature accessible via PubMed or ClinicalTrials.gov. The transition to modafinil as the preferred clinical agent meant adrafinil did not undergo the large Phase III RCT program that modafinil did.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### 🚨 Safety-Critical Flags

1. **⚠️ CRITICAL: Pharmacological class error in seed data.** The seed data lists "Alpha-2 adrenergic receptor antagonist" as a pharmacological class. This contradicts NCATS (α1-adrenergic receptor agonist), Bourin 1988 (alpha-1 central stimulant), and the mechanistic literature. This is not a minor labeling difference — alpha-2 antagonist and alpha-1 agonist describe completely different receptor mechanisms. **Requires editorial correction before publication.**

2. **⚠️ Orofacial dyskinesia risk not documented in seed data.** The Thobois et al. 2004 case report [Ref 4] documents persistent orofacial dyskinesia requiring tetrabenazine treatment, not self-resolving over 4 months. This should appear in contraindications/adverse events section. Risk appears highest in chronic use.

3. **⚠️ Oral contraceptive interaction not mentioned.** The CYP3A4 induction by modafinil (clinically confirmed, Robertson 2002 [Ref 38]) reduces efficacy of oral contraceptives. This is a high-priority drug interaction for users who are not post-menopausal.

4. **⚠️ Hepatic risk: no primary literature but mechanistic concern.** The extra hepatic processing required for adrafinil vs modafinil raises theoretical hepatotoxicity concern. No primary literature directly documents adrafinil-caused liver injury, but liver monitoring is recommended for chronic use. The LiverTox rating for modafinil (Category E: unlikely) may not fully apply to adrafinil.

### Data Gaps

5. **No human PK data for adrafinil.** All human pharmacokinetic parameters are from modafinil (the active metabolite). There are no published human Tmax, Cmax, AUC, or bioavailability studies for adrafinil as parent compound.

6. **No published binding affinity data (Ki/IC50) for adrafinil.** At DAT, NET, alpha-1 receptors, or any other target. Receptor binding data is entirely inferred from modafinil studies.

7. **No dedicated adrafinil clinical trials.** Clinical data comes from proprietary French programs (1980s–1990s) not published in indexed literature.

8. **Melting point discrepancy.** Vendor data: 140–142°C vs ChemicalBook: 159–160°C. Requires resolution against a primary analytical source.

9. **"Characterization: emerging" in seed data is incorrect.** Adrafinil is a known, discontinued pharmaceutical (developed 1974, marketed 1985–2011). This classification should be corrected to "discontinued" or "research chemical."

10. **Dose data not verified against human clinical studies.** The seed dose ranges (threshold 100 mg, common 250–400 mg, heavy 600+ mg) are consistent with Olmifon prescribing practice and modafinil equivalences but have not been confirmed against a primary clinical source. Olmifon was prescribed at 300–1200 mg/day in the elderly — the seed heavy dose ceiling (600 mg) may be conservative relative to historical prescribing.

11. **Duration data source unclear.** The seed duration data is consistent with modafinil PK (half-life ~12–15 hours) [Ref 23] but appears to be derived from structural/class inference. No adrafinil-specific human duration data found.

12. **Dependence/tolerance data not sourced from literature.** The seed tolerance values ("half-life: 5 days, full reset: 1.5 weeks") cannot be verified against published sources for adrafinil or modafinil specifically. These appear to be community consensus estimates.

13. **Stereochemical activity of adrafinil enantiomers unknown.** Chiral separation is established [Ref 11, 15], but no differential pharmacological data for (+)- vs (−)-adrafinil enantiomers was found. Contrast: R-modafinil (armodafinil) has confirmed longer half-life and is marketed separately.

14. **No interaction data for MAOIs, lithium, or anticonvulsants** specific to adrafinil/modafinil.